Synopsis
Plan collaborative psychotropic withdrawal or switching, distinguish withdrawal from relapse and new toxicity, and use medicine-specific tapering and washout rules to avoid preventable destabilisation.
- Establish why treatment is changing, whether the original indication remains active, and what successful reduction would mean to the person.
- For most psychotropics avoid abrupt cessation unless serious toxicity or another urgent medical circumstance makes rapid withdrawal necessary.
- Antidepressant reductions should usually be stepwise and proportional to the current dose, with smaller decrements towards the end.
- Withdrawal may begin soon after a reduction and include dizziness, nausea, electric-shock sensations, vivid dreams and unusual anxiety.
- A direct switch, cross-taper and taper-then-washout are distinct strategies; choose from the exact drug pair and interaction profile.
- Fluoxetine has a long-lived active metabolite and requires a five- to six-week washout before an MAOI under specialist advice.
- A planned lithium stop for bipolar disorder should take at least four weeks and preferably up to three months, even after another antimanic drug starts.
- A pause in reduction can be a sensible response to symptoms and is not evidence that the person has failed.
Key red flags
Fever, clonus, hyperreflexia and agitation during an antidepressant switch suggests serotonin toxicity and requires urgent cessation assessment and medical treatment.
Seizure or delirium after abrupt benzodiazepine withdrawal is a medical emergency, particularly after prolonged high-dose use.
New reduced need for sleep, overactivity, disinhibition or psychosis during mood-stabiliser reduction needs prompt psychiatric review.
Investigation priorities
Determine actual exposure rather than relying on the written schedule.
Management branches
The person and prescriber decide that reducing or stopping a psychotropic is appropriate.
- Review benefit, relapse history, previous withdrawal and current supports, agreeing which medicine to address first.
- Write stepwise reductions proportionate to the current dose and allow adequate time at each step for symptoms to settle.
- Arrange follow-up and a contingency plan before the first reduction, adjusting the pace according to tolerability and clinical risk.